<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240212060966N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-21</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of surgical site skin preparation with povidone-iodine solution at two different temperatures on the antimicrobial effect and surgical wound infection</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of surgical site skin preparation with povidone-iodine antiseptic at two different temperatures on the microbial load and surgical site infection in laparotomy patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-04-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>126</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/75499</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Randomization method: simple randomization
Randomization tool: using a table of random numbers made by the computer, Blinding description: In this research, single blinding will be used; So that the samples will not be informed about the antiseptic temperature used for them. But the researcher and the surgical team will know the antiseptic temperature used for each sample.</study_design>
      <phase>3</phase>
      <hc_freetext>Surgical site infection.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: surgical site Skin preparation will be done in two stages. At first, before starting the skin preparation process, a culture will be taken from the skin of the surgical site with a sterile swab. In this way, an initial culture sample will be taken using a wet swab soaked in physiological serum and the swab will be rubbed on the blood agar culture medium. Then, in the initial stage of skin preparation, povidone-iodine 7.5% will be used at a temperature of 22 degrees Celsius. The skin preparation will be done in a circular manner from the center of the surgical incision to the periphery and this will be done with 3 separate sterile gauzes. After performing the initial stage of skin preparation,we will wait for 5 minutes and then the antiseptic residue will be dried by a sterile cloth. Before starting the secondary stage, a skin culture will be taken from the surgical site. The second culture sample will be taken using a sterile swab dipped in physiological serum. In this way, the swab will be rubbed on the blood agar medium. Then, in the secondary stage, povidone-iodine 10% will be used at a temperature of 35 degrees Celsius. Skin preparation will be done in a circular manner from the center of the surgical incision to the periphery by 3 separate gas sterilizers. After performing the secondary stage of skin preparation, we will wait for 5 minutes and then the antiseptic residue will be dried by a sterile cloth. Again, a culture will be taken from the skin of the surgical site with a sterile swab dipped in physiological serum. In this way, the swab will be rubbed on the blood agar culture medium. Then, the surgical site will be covered with sterile cloths and sterile plastic covers, and the surgical process will continue. The culture samples will be sent to the laboratory to determine the microbial load. 24 hours after the surgery, the dressing of the surgical site will be changed for the first time by the researcher and the relevant doctor. The surgical site will be observed and examined for signs of surgical site infection. The symptoms will be recorded in the researcher's form for recording surgical site infection symptoms. The patient will be trained. The form for recording the symptoms of surgical site infection will be provided to the patient so that he or she can check the surgical site within one month after the surgery and record the symptoms in the said form. Then at the end of 30 days of the said form will be collected by the researcher. Finally, two groups will be compared. Intervention 2: Control group: Surgical site skin preparation will be done in two stages. First, before starting the skin preparation process, a sterile swab will be taken from the skin of the surgical site. In this way, a primary culture sample will be taken using a wet swab dipped in physiological serum and rubbed on the blood agar culture medium. Then, in the initial stage of skin preparation, povidone iodine 7.5% will be used at a temperature of 22 degrees Celsius. Skin preparation will be done in a circular manner from the center of the surgical incision to the periphery, and this will be done with 3 separate sterile gauzes. After performing the initial stage of skin preparation, we will wait for 5 minutes and then the antiseptic residue will be dried by a sterile cloth. Before starting the secondary stage, the second culture will be taken from the skin of the surgical site. Then, in the secondary stage, povidone-iodine 10% at 22°C will be used. The preparation of the skin will be done in a circular manner from the center of the surgical incision to the periphery by 3 separate gas sterilizers. After performing the secondary stage of skin preparation, we will wait for 5 minutes and then the antiseptic residue will be dried by a sterile cloth. Again, a culture will be taken from the skin of the surgical site with a sterile swab dipped in physiological serum. Then, the surgical site will be covered with sterile cloths and sterile plastic covers, and the surgical process will continue. Culture samples will be sent to the laboratory to determine the microbial load. 24 hours after the surgery, the dressing of the surgical site will be changed for the first time by the researcher and the relevant doctor. The surgical site will be observed and examined for signs of surgical site infection. The symptoms will be recorded in the researcher's form for recording surgical site infection symptoms. The patient will be trained. The form for recording the symptoms of surgical site infection will be provided to the patient so that he or she can check the surgical site within one month after the surgery and record the symptoms in the said form. Then at the end of 30 days of the said form will be collected by the researcher. Finally, two groups will be compared.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fardin Amiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Paramedicine,Iran University of Medical Sciences, between the intersection of Sheikh Fazlullah Nouri and Shahid Chamran, Shahid Hammat highway, next to milad tower, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 8670 4600</telephone>
        <email>amiri.fa@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fardin Amiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Paramedicine,Iran University of Medical Sciences, between the intersection of Sheikh Fazlullah Nouri and Shahid Chamran, Shahid Hammat highway, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 8670 4600</telephone>
        <email>amiri.fa@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18 to 55 years
Having at least a diploma degree
No diabetes
No history of laparotomy surgery
Body mass index less than 35
Absence of immune system deficiency and no use of immunosuppressive drugs
Absence of local infection near the surgical site or systemic infection
Not being allergic to povidone-iodine antiseptic
No history of malignancy and radiation therapy
Absence of severe skin rash at the surgical site
Not using broad-spectrum antibiotics within a month before going to the hospital
having Elective surgery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Emergency laparotomy surgery
Disruption in the surgical process that leads to the contamination of the instruments or the surgical field
immune system deficiency and using immunosuppressive drugs
having diabetes
allergic to povidone-iodine antiseptic
The presence of rashes and severe skin diseases at the surgical site
using broad-spectrum antibiotics within a month before going to the hospital
morbid obesity</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: surgical site Skin preparation will be done in two stages. At first, before starting the skin preparation process, a culture will be taken from the skin of the surgical site with a sterile swab. In this way, an initial culture sample will be taken using a wet swab soaked in physiological serum and the swab will be rubbed on the blood agar culture medium. Then, in the initial stage of skin preparation, povidone-iodine 7.5% will be used at a temperature of 22 degrees Celsius. The skin preparation will be done in a circular manner from the center of the surgical incision to the periphery and this will be done with 3 separate sterile gauzes. After performing the initial stage of skin preparation,we will wait for 5 minutes and then the antiseptic residue will be dried by a sterile cloth. Before starting the secondary stage, a skin culture will be taken from the surgical site. The second culture sample will be taken using a sterile swab dipped in physiological serum. In this way, the swab will be rubbed on the blood agar medium. Then, in the secondary stage, povidone-iodine 10% will be used at a temperature of 35 degrees Celsius. Skin preparation will be done in a circular manner from the center of the surgical incision to the periphery by 3 separate gas sterilizers. After performing the secondary stage of skin preparation, we will wait for 5 minutes and then the antiseptic residue will be dried by a sterile cloth. Again, a culture will be taken from the skin of the surgical site with a sterile swab dipped in physiological serum. In this way, the swab will be rubbed on the blood agar culture medium. Then, the surgical site will be covered with sterile cloths and sterile plastic covers, and the surgical process will continue. The culture samples will be sent to the laboratory to determine the microbial load. 24 hours after the surgery, the dressing of the surgical site will be changed for the first time by the researcher and the relevant doctor. The surgical site will be observed and examined for signs of surgical site infection. The symptoms will be recorded in the researcher's form for recording surgical site infection symptoms. The patient will be trained. The form for recording the symptoms of surgical site infection will be provided to the patient so that he or she can check the surgical site within one month after the surgery and record the symptoms in the said form. Then at the end of 30 days of the said form will be collected by the researcher. Finally, two groups will be compared.</i_keyword>
      <i_keyword>Control group: Surgical site skin preparation will be done in two stages. First, before starting the skin preparation process, a sterile swab will be taken from the skin of the surgical site. In this way, a primary culture sample will be taken using a wet swab dipped in physiological serum and rubbed on the blood agar culture medium. Then, in the initial stage of skin preparation, povidone iodine 7.5% will be used at a temperature of 22 degrees Celsius. Skin preparation will be done in a circular manner from the center of the surgical incision to the periphery, and this will be done with 3 separate sterile gauzes. After performing the initial stage of skin preparation, we will wait for 5 minutes and then the antiseptic residue will be dried by a sterile cloth. Before starting the secondary stage, the second culture will be taken from the skin of the surgical site. Then, in the secondary stage, povidone-iodine 10% at 22°C will be used. The preparation of the skin will be done in a circular manner from the center of the surgical incision to the periphery by 3 separate gas sterilizers. After performing the secondary stage of skin preparation, we will wait for 5 minutes and then the antiseptic residue will be dried by a sterile cloth. Again, a culture will be taken from the skin of the surgical site with a sterile swab dipped in physiological serum. Then, the surgical site will be covered with sterile cloths and sterile plastic covers, and the surgical process will continue. Culture samples will be sent to the laboratory to determine the microbial load. 24 hours after the surgery, the dressing of the surgical site will be changed for the first time by the researcher and the relevant doctor. The surgical site will be observed and examined for signs of surgical site infection. The symptoms will be recorded in the researcher's form for recording surgical site infection symptoms. The patient will be trained. The form for recording the symptoms of surgical site infection will be provided to the patient so that he or she can check the surgical site within one month after the surgery and record the symptoms in the said form. Then at the end of 30 days of the said form will be collected by the researcher. Finally, two groups will be compared.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Microbial load. Timepoint: microbial cultures will be taken in three stages before the surgical site skin preparation, after the initial stage of disinfection of the surgical site and after the secondary stage of disinfection of the surgical site with povidone-iodine 10%. Method of measurement: taking microbial culture and counting microbial colonies 24 hours after incubation.</prim_outcome>
      <prim_outcome>Surgical site infection. Timepoint: Observation and examination of the surgical wound after 24 hours and 30 days after surgery. Method of measurement: Observing and examining the surgical wound and entering the symptoms in the surgical site infection checklist.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-02-05</approval_date>
        <contact_name>Ethics committee of iran University of Medical Sciences</contact_name>
        <contact_address>Faculty of allied medicine, Iran univarsity of medical sciences ,Hemmat highway, next to the milad tower, tehran, iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
